Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by COSTELLO, H. D.
Right arrow Articles by SNIDER, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by COSTELLO, H. D.
Right arrow Articles by SNIDER, D. E., Jr.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Vol. 111, No. 1: 67-74
Copyright © 1980 by The Johns Hopkins University School of Hygiene and Public Health

research-article

THE INCIDENCE OF CANCER AMONG PARTICIPANTS IN A CONTROLLED, RANDOMIZED ISONIAZID PREVENTIVE THERAPY TRIAL

HELEN D. COSTELLO and DIXIE E. SNIDER, Jr.1

1Research and Development Branch, Tuberculosis Control Division, Bureau of State Services, Center for Disease Control Atlanta, GA 30333

Requests for reprints should be addressed to Technical Information Services, Bureau of State Services, at this address

Cancer morbidity and mortality were examined among 11,894 Puerto Rican participants in a US Public Health Service preventive therapy trial begun in 1957. The mean duration of follow-up was 18 years (range 16–19 years). No statistically significant difference in overall cancer rates was observed between the participants in the trial assigned isoniazid and those assigned placebo. There were also no significant differences between the groups when rates for specific types of cancer and age-speciflc cancer rates were compared. No trend toward an increasing cancer rate in the isoniazid group was observed with the passage of time. The mortality rate due to cancer was similar in the two groups. These data coupled with other information reported in the literature provide substantial evidence that isoniazid, when given in the usual therapeutic doses, is not carcinogenic in humans.

carcinogens; isoniazed; neoplasms; tuberculosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
K. Shichikawa, K. Inoue, S. Hirota, A. Maeda, H. Ota, M. Kimura, T. Ushiyama, and M. Tsujimoto
Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996
Ann Rheum Dis, December 1, 1999; 58(12): 751 - 756.
[Abstract] [Full Text]

Home page
 Hum Exp ToxicolHome page
R. Saffhill, S. Fida, M. Bromley, and P.J. O'Connor
Promutagenic Alkyl Lesions are Induced in the Tissue DNA of Animals Treated with Isoniazid
Human and Experimental Toxicology, July 1, 1988; 7(4): 311 - 317.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.